MORRISTOWN, N.J., March 7, 2025 -- Alvogen Pharma US, Inc. ("Alvogen" or the "Company"), a privately owned US-based pharmaceutical company, announced the successful completion of a comprehensive refinancing of its capital structure. Alvogen raised a $553 million first lien term loan due 2028 (the "First Lien Term Loan") and a $116 million second lien term loan due 2029 (the "Second Lien Term Loan") to refinance its existing secured term loan due 2025, as well as to pay related fees and expenses.
"We are pleased to have completed this important refinancing for Alvogen, which strengthens our capital structure in terms of maturity and continued access to substantial liquidity, while also preserving flexibility to execute on our long-term business strategy," said Lisa Graver, Chief Executive Officer of Alvogen.
In addition to the First Lien and Second Lien Term Loans, Alvogen also announced it had successfully amended and extended its existing $240 million ABL revolving credit facility.
Goldman Sachs & Co. LLC and Jefferies LLC served as joint financial advisor and White & Case LLP served as legal counsel to Alvogen on this transaction.
ABOUT ALVOGEN
Alvogen is a privately-owned company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products. Alvogen is growing its portfolio of complex, high value products including complex inhalation, injectables and strategic 505(b)(2) products. Presently, Alvogen has over 50 products currently on market and extensive R&D capabilities fueling its growing pipeline. Key shareholders in Alvogen include Aztiq ("Azqtic"), an Icelandic healthcare investment firm founded by Robert Wessman, CVC Capital Partners ("CVC") and Temasek Holdings of Singapore ("Temasek"). For more information, please visit www.alvogen.com.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
